Should I buy or sell Verve Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares. View VERV analyst ratings or view top-rated stocks .

What is Verve Therapeutics' stock price target for 2024?

8 analysts have issued 12-month price objectives for Verve Therapeutics' stock. Their VERV share price targets range from $15.00 to $55.00. On average, they predict the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 404.6% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts .

How have VERV shares performed in 2024?

Verve Therapeutics' stock was trading at $13.94 at the beginning of 2024. Since then, VERV shares have decreased by 53.1% and is now trading at $6.54. View the best growth stocks for 2024 here .

When is Verve Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VERV earnings forecast .

How were Verve Therapeutics' earnings last quarter?

Verve Therapeutics, Inc. (NASDAQ:VERV) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.14. The firm earned $5.14 million during the quarter, compared to analyst estimates of $3.95 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 39.33% and a negative net margin of 1,701.70%.

What ETFs hold Verve Therapeutics' stock?

ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , ARK Genomic Revolution ETF (ARKG) , Global X Genomics & Biotechnology ETF (GNOM) and Direxion Moonshot Innovators ETF (MOON) . ARK Innovation ETF (ARKK) .

When did Verve Therapeutics IPO?

Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO.

Who are Verve Therapeutics' major shareholders?

Verve Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.10%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger , Andrew D Ashe , Burt A Adelman , Cormorant Asset Management, Lp, Fmr Llc, Joan Nickerson, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan . View institutional ownership trends .

How do I buy shares of Verve Therapeutics?

Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VERV

Verve Therapeutics (VERV) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free VERV Stock Alerts

$6.51

-0.15 (-2.25%)

(As of 03:27 PM ET)

Compare

Today's Range: $6.42
▼
$6.80
50-Day Range: $6.66
▼
$17.96
52-Week Range: $6.42
▼
$21.42

Volume: 706,550 shs
Average Volume: 1.23 million shs
Market Capitalization: $544.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.00

Get Verve Therapeutics alerts:

Verve Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 404.6% Upside
$33.00 Price Target
Short Interest: Bearish
28.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.32
Based on 6 Articles This Week
Insider Trading: Selling Shares
$12,475 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.92) to ($2.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

428th out of 918 stocks

Pharmaceutical Preparations Industry

192nd out of 419 stocks

3.4

Analyst's Opinion

Consensus Rating
Verve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Verve Therapeutics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
28.03% of the float of Verve Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Verve Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Verve Therapeutics has recently increased by 8.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Verve Therapeutics does not currently pay a dividend.
Dividend Growth
Verve Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERV.

2.4

News and Social Media Coverage

News Sentiment
Verve Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Verve Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
MarketBeat Follows
9 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verve Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,475.00 in company stock.
Percentage Held by Insiders
21.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Verve Therapeutics are expected to grow in the coming year, from ($2.92) to ($2.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verve Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verve Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verve Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Verve Therapeutics Stock (NASDAQ:VERV)

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VERV Stock News Headlines

April 4, 2024 | insidertrades.com

Joan Nickerson Sells 1,514 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) Stock

April 18, 2024 | wsj.com

GV’s Newest Life Sciences General Partner Pursues Precision Treatments

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 18, 2024 | americanbankingnews.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Moderate Buy" by Brokerages

April 18, 2024 | msn.com

Verve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77

April 13, 2024 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Up to $8.01

April 12, 2024 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down to $8.75

April 11, 2024 | benzinga.com

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | americanbankingnews.com

Research Analysts Issue Forecasts for Verve Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:VERV)

April 9, 2024 | markets.businessinsider.com

Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery

April 9, 2024 | msn.com

A Bold Gene-Editing Solution Began Testing—Then Hit the Strangest Twist

April 9, 2024 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Receives New Coverage from Analysts at HC Wainwright

April 6, 2024 | fool.com

After a Serious Setback, Is Verve Therapeutics a Buy?

April 3, 2024 | msn.com

Gene Editing Experiment Halted as Patient Gets Weird Side Effects

April 3, 2024 | seekingalpha.com

Verve Therapeutics: An Update On Human CRISPR

April 3, 2024 | seekingalpha.com

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

April 2, 2024 | msn.com

Verve Therapeutics pauses enrollment of patients in trial for its gene therapy to treat high cholesterol after severe side effect

April 2, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Verve Therapeutics with Strategic Focus on Promising VERVE-102 Program

April 2, 2024 | bizjournals.com

Verve’s stock tumbles as biotech pauses gene editing trial over safety concerns

April 2, 2024 | marketwatch.com

Verve Therapeutics Pauses Enrollment in Trial of Gene Editing Medicine After Serious Adverse Event

April 2, 2024 | markets.businessinsider.com

Verve Therapeutics To Halt Enrollment In Heart-1 Phase 1b Trial Of VERVE-101; Stock Falls

April 2, 2024 | msn.com

Verve drops after pausing enrollments in trial for lead asset

April 2, 2024 | msn.com

Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback

April 2, 2024 | finance.yahoo.com

Verve Falls as Gene-Editing Trial Paused on Safety Issues

April 2, 2024 | finance.yahoo.com

Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects

April 2, 2024 | reuters.com

Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels

See More Headlines

Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VERV
CUSIP: N/A
CIK: 1840574
Web: vervetx.com
Phone: 617-603-0070
Fax: N/A
Employees: 255
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.00
High Stock Price Target: $55.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +395.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-200,070,000.00
Net Margins: -1,701.70%
Pretax Margin: -1,699.21%
Return on Equity: -39.33%
Return on Assets: -30.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.24
Quick Ratio: 17.24

Sales & Book Value

Annual Sales: $11.76 million
Price / Sales: 47.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.31 per share
Price / Book: 0.91

Miscellaneous

Outstanding Shares: 83,620,000
Free Float: 65,725,000
Market Cap: $556.91 million
Optionable: Optionable
Beta: 1.70

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Burt A. Adelman M.D. (Age 72)
Co-Founder & Independent Chairman of the Board
Comp: $87.55k
Dr. Sekar Kathiresan M.D. (Age 52)
Co-Founder, CEO & Director
Comp: $899.55k
Mr. Andrew D. Ashe J.D. (Age 57)
President, COO & General Counsel
Comp: $703.85k
Dr. Andrew Bellinger M.D. (Age 45)
Ph.D., Chief Scientific Officer
Comp: $703.85k
Dr. Kiran Musunuru M.D.
M.P.H., Ph.D., Co-Founder
Dr. J. Keith Joung M.D.
Ph.D., Co-Founder
Dr. Anthony Philippakis M.D.
Ph.D., Co-Founder & Scientific Advisory Board Member
Dr. Barry S. Ticho FACC (Age 63)
M.D., Ph.D., Co-Founder
Mr. Issi Rozen M.B.A.
Co-Founder & Strategic Advisor
Ms. Allison Dorval (Age 48)
CFO & Principal Accounting Officer
Comp: $260.93k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VERV Stock Analysis - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VERV shares.
View VERV analyst ratings or view top-rated stocks.
What is Verve Therapeutics' stock price target for 2024?: 8 analysts have issued 12-month price objectives for Verve Therapeutics' stock. Their VERV share price targets range from $15.00 to $55.00. On average, they predict the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 404.6% from the stock's current price.
View analysts price targets for VERV or view top-rated stocks among Wall Street analysts.
How have VERV shares performed in 2024?: Verve Therapeutics' stock was trading at $13.94 at the beginning of 2024. Since then, VERV shares have decreased by 53.1% and is now trading at $6.54.
View the best growth stocks for 2024 here.
When is Verve Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our VERV earnings forecast.
How were Verve Therapeutics' earnings last quarter?: Verve Therapeutics, Inc. (NASDAQ:VERV) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.14. The firm earned $5.14 million during the quarter, compared to analyst estimates of $3.95 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 39.33% and a negative net margin of 1,701.70%.

What ETFs hold Verve Therapeutics' stock?: ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM) and Direxion Moonshot Innovators ETF (MOON).ARK Innovation ETF (ARKK).
When did Verve Therapeutics IPO?: Verve Therapeutics (VERV) raised $201 million in an initial public offering on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO.
Who are Verve Therapeutics' major shareholders?: Verve Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.10%) and Green Alpha Advisors LLC (0.03%). Insiders that own company stock include 2017 Gp LLC Gv, Allison Dorval, Andrew Bellinger, Andrew D Ashe, Burt A Adelman, Cormorant Asset Management, Lp, Fmr Llc, Joan Nickerson, Krishna Yeshwant, Logos Global Management Lp and Sekar Kathiresan.
View institutional ownership trends.
How do I buy shares of Verve Therapeutics?: Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Verve Therapeutics (VERV) Stock Price, News & Analysis

Verve Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Verve Therapeutics Stock (NASDAQ:VERV)

VERV Stock Price History

VERV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VERV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™